Travere Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Feb 20, 2024 and accepted by EDGAR at Feb 20, 2024, 13:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $45.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2023-01-01 to 2023-12-31 | $145.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | $11.4m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | $265.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-10-01 to 2023-12-31 | −$94.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$388.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $11.3m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $223.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | −$90.2m | us-gaap:NetIncomeLoss |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$111.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-10-01 to 2023-12-31 | −$1.18 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$1.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | −$1.18 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$1.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 74,267,418 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$280.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $668.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $58.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $616.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $788.9m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $177.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $588.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $200.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001438533-24-000005. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.